Months af­ter re­org, Adap­ti­m­mune merges with fel­low cell ther­a­py de­vel­op­er

Adap­ti­m­mune is merg­ing with TCR² Ther­a­peu­tics in a bid to cre­ate a T cell ther­a­py de­vel­op­er aimed at sol­id tu­mors.

The all-stock deal brings to­geth­er both com­pa­nies’ lead can­di­dates — Adap­ti­m­mune’s afa­mi-cel, which tar­gets MAGE-A4, and TCR²’s mesothe­lin-tar­get­ing ga­vo-cel — as well as a pipeline of can­di­dates en­gi­neered with T cell re­cep­tors, or TCRs. Un­like CAR-T ther­a­pies, TCR-T is not lim­it­ed to sur­face anti­gens but can tar­get anti­gens in­side can­cer cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER